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Congenital anomalies are the cause of perinatal death in 20-25% 
of the cases, while 3% of children are born with malformation of varying 
size. The objective of this study was to examine the predictive value and 
define the credibility ratio of the combined test results. Of 317 examined 
pregnant women, we had sixteen (5.05%) with the result of pathological 
karyotype  after  amniocentesis  including:  nine  (2.84%)  with  fetal 
numerical aberrations and seven (2.21%) with fetal structural aberrations. 
While determining the ultrasonographic parameters of the combined test 
we used the standards of the Fetal Medicine Foundation. We carried out 
the quantitative settings of free β-HCG and PAPP-A from vein blood of 
patients  by  applying  commercial  tests  of  firm  DPC-USA.  Tests  were 
based  on  the  analytical  immunochemiluminescence  assay  and  were 
realized by using the automated analyzer IMMULITE 2000. Manufacturer 
of the analyzer is also the firm DPC-USA. Sensitivity of the test is 94%, 
and specificity is 99%. Positive likelihood ratio [likelihood ratio test (LR 286                                                                                   GENETIKA, Vol. 43, No. 2, 285-296, 2011 
+)] is 94.00, a  negative likelihood ratio is [likelihood ratio test (LR-)] 
12:06.  Pretest  probability  that  pregnant  women  carries  fetus  with 
chromosomal  abnormality  is  1:250  or  0004.  Posttest  odds  after  the 
combined test to discover this abnormality is 0.3760, and probability of 
the same case is 0.2732 if it happens that the test result is positive. The 
result of our study confirms the justification of combined test usage in 
routine  clinical  practice,  since  the  posttest  odds  rate  in  the  case  of  a 
positive  screening  increases  several  times  over  (almost  90  times),  the 
probability of detecting a chromosomal abnormality was about 70 times. 
Combined  screening  test  if  used  methodologically  correct,  has  a  high 
predictive value in detecting fetal congenital anomalies. 
Key words: family, migraine, recurrent headache. 
 
INTRODUCTION 
Congenital  anomalies  are  the  cause  of  perinatal death  in  20-25%  of  the 
cases, while 3%  of children  are born  with  malformation of  varying size. Usable 
value of the screening test is estimated on the basis of its sensitivity, specificity and 
possibility of the disease in case the result is positive. By combining the values of 
pregnancy-associated  plasma  protein  A  (PAPP-A)  and  free  beta-subunit  of 
choriogonadotropin (Free β-HCG) in serum with nuchal translucency (NT) diameter 
(Combined test), the possibility of detecting DS is rising up to considerable 90% 
with  5%  of  false  positive  findings,  SPENCER  (2001).  The  testing  is  being  done 
between 11 and 13+6 weeks of gestation. If the result happens to be positive, some 
invasive methods of prenatal diagnosis are suggested to the pregnant woman. A limit 
value of the combined test is 1: 250. Special problem is the test result interpretation. 
According to the literature data, even 32% of pregnant women answered that after 
getting the results and talking to the doctor, WALD et al. (1999), they didn’t know 
what the term “high risk” really meant.  
Research objective was: 
1.  To  examine  the  sensitivity  and  specificity  of  ultrasonographic  (nuchal 
translucency - NT) and biochemical (Free β-HCG and PAPP-A) markers as 
parameters of the combined test and amniocentesis in diagnostics of congenital 
fetal anomalies.  
2.  To set the credibility ratio of the combined test results. 
 
 
MATERIALS AND METHODS 
Prospective,  observational  study  was  conducted  at  the  Gynecology  and 
Obstetrics Clinic at Clinical Center Kragujevac (GOC, CC Kragujevac) in the period 
2008-2009 on singleton intrauterine pregnancies in the first trimester of pregnancy. 
Clinical and experimental model of study was used throughout the research. Ethics 
Committee  at  the  CC  Kragujevac  confirmed  the  rightness  of  this  study  and 
authorized its conduct. 317 pregnant women were included in the examination and 
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examinations were conducted on the “Aloka Prosound 3500” apparatus at GOC CC 
Kragujevac. Pregnancy was 11-13+6 weeks of gestation. Crown-rump length (CRL) 
of the fetus was between 45 and 84 mm. While measuring fetal NT we used the 
ultrasound apparatus of high resolution with the option“cine loop” so that image 
could be returned by calipers that allow measurement of one decimal.  Screen image 
on which NT was measured, encompassed only the head and the upper part of fetal 
rib cage. We used the maximum enlargement, so that little movement of the caliper 
altered the  diameter  for  only  0,1mm.  The  nuchal  translucency  was  measured  by 
transvaginal approach of color Doppler technique with fetus in neutral position. We 
measured the maximal thickness of subcutaneous illumination between the skin and 
soft tissue located above cervical part of the fetal spine. We set the calipers on lines 
that define the fold, so that they were barely visible on the white limit line of the 
accumulation  behind  the  neck.  During  the  examinations  we  conducted  more 
measurements and took into consideration only the highest thickness of the nuchal 
translucency. We carried out the quantitative settings of free β-HCG and PAPP-A 
from vein blood of patients by applying commercial tests of firm DPC-USA. Tests 
were based on the analytical immunochemiluminescence assay and were realized by 
using the automated analyzer IMMULITE 2000. Manufacturer of the analyzer is also 
the firm DPC-USA.  
On  all  pregnant  women  included  in  the  research  we  carried  out  the 
amniocentesis  by  standard  transabdominal  procedure  with  the  ultrasound  control, 
using “free hand” technique, in gestational age of 16 to 17+6 weeks of gestation. We 
did the puncture by needles with mandrene of 20-22G thickness and aspirated 15-20 
ml of amniotic fluid into a syringe without rubber seal. The amniotic fluid sample we 
received, we were delivering to the Cytogenetics laboratory at GOC CC Krаgujevаc. 
All received results were deposited into the unique data base with required logistic 
control.  
 
RESULTS  
After  conducted  combined  test  in  total  sample  of  pregnant  women,  we  find  the 
following individual values of the examined parameters (Table 1). 
 
Table 1 Difference between values of free beta-subunit of HCG, PAPPA and NT in the 
examined groups of pregnant women (total sample); n=317 
Parameters  Free-β HCG  
In ml/ml 
PAPP-A In 
ml/ml 
NT 
mm 
Pathological 
karyotype 
114.00  1.36  2.55 
Physiological 
karyotype 
19.20  1.84  1.90 
Mann Whitney (U)  704.5  2191  621.5 
p  0.000  0.543  0.000 
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We notice the statistically significant difference in values of free β HCG 
and  NT  in  examined  groups  of  pregnant  women  (p<  0.05).  Parameter  PAPP-A 
doesn’t  show  statistically  significant  difference  in  examined  groups  of  pregnant 
women. We also find the same characteristics of the examined parameters in the 
ROC curves analysis in the examination of predictive characteristics of specified 
parameters. (Figure 1 and 2). 
ROC Curve
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Figure 1. Probability of the predictive value of free fraction beta HCG 
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Field below ROC curve 0.715 (95% Confidence interval 0.508 – 0.921) 
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The  distribution  of  parameter  values  necessary  for  the  methodologically 
regular  measurement  of  the  fetal  NT  according  to  the  instruction  of  the  Fetal 
Medicine Foundation - FMF, is on the table 2. 
 
Table  2.  Review  of  the  middle  values  (MV)  and  standard  deviations  (SD)  of  the 
ultrasonographic  parametres  and  gestational  age  in  total  sample  of  pregnant 
women 
Parameters  Pathological 
karyotype =16 
Control 
group=301 
P 
Nuchal translucency 
(mm) 
2.49±0.37  1.92±0.39  <0.05 
Crown-rump length 
(mm) 
60.12±8.48  64.83±8.23  p>0,05 
Gestational age (days)  85.69±3.98  87.40±7.10  p>0.05 
 
 
Analysis of the value distribution of the NT thickness measurement showed 
that the  distribution  was regular and that measurements were being  set regularly 
around the median (44% below and 56% above median), which was in accordance 
with the criteria for quality control established by  
Fetal Medicine Foundation (FMF) and was supposed to be 40- 60% above 
median. Distribution of fetal NT for given CRL in examination is no different from 
the established distribution of FMF used as a standard. On the basis of that, our 
measurements of NT thickness can be considered regularly conducted and usable in 
further examination. 
Diameter of nuchal translucency did significantly statistically differ in the 
examined groups of pregnant women (p<0.05). Crown-rump length and gestational 
age were not different statistically (p>0.05). Using the contingency table, we set the 
predictive value of the combination of ultrasonographic and biochemical markers 
after taking over the results of amniocentesis (Table 3). 
 
Table 3 Contingency table formed on the basis of data processing in the total sample of 
pregnant women after amniocentesis 
Test result  Disease present  Disease absent  Total 
Positive  SP =15  LP= 1  SP+LP  =16 
Negative  LN= 3  SN=298  LN+SN = 301 
Total  SP+LN =18  LP+SN =299  N  = 317 
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Table  4.  Calculation  of  the  probabilities  and  predictive  values  of  the  parameters  of  the 
combined test in relation to the result of the early amniocentesis  
Parameter  Value  Confidence interval 
95% CI 
Sensitivity  0.9375  0.6977 -0.9984 
Specificity  0.9900  0.9712 - 0.9979 
Positive predictive 
value 
0.8333  0.5858 - 0.9642 
Negative predictive 
value 
0.9967  0.9815 - 0.9999 
        Prevalence  0.0505  0.0291 - 0.0807 
False positive rate  0.0100  0.0046- 0.0245 
False negative rate  0.0625  0.0145- 0.0998 
Positive likelihood 
ratio LR+ 
94.0000  30.2937 - 292.0653 
Negative likelihood 
ratio LR- 
0.0631  0.01746 - 1.2712 
Overall test accuracy  0.9873  0.07215- 0.9981 
 
Estimation  of  probability  that  some  disease  is  present  before  testing  is 
called pretest probability (“а priori probability”). Pretest probability is received on 
the  basis  of  available  information  about  the  patient,  also  including  the  testing 
previous to the actual one. Estimation of the probability of disease after the testing is 
called posttest probability (“а posteriori probability”). Posttest probability is less or 
higher than pretest probability depending on the test results. Measures of diagnostic 
accuracy  (sensitivity,  specificity)  can  not  directly  answer  the  important  clinical 
questions: 
1. If the disease pretest probability is known, and the examinee is positive on the test, 
what is the probability that he/she really has the disease? 
2. If the disease pretest probability is known, and the examinee is negative on the 
test, what is the probability that he/she really doesn’t have the disease? 
These questions can be answered by application of the pretest odds of the disease 
and the credibility ratio. Disease odds ratio is the ratio of probability that the disease 
is present (p) and probability that is not present (1–p): 
Odds=p/1-p 
According to that, pretest disease odds are: 
Pretest odds=pretest probability /1- pretest probability 
Likelihood ratio (LR) is the probability ratio of the certain test result (+ or -) of the 
examinee who has the disease divided with the probability of the same result of the 
person who doesn’t have the disease. Two types of likelihood can be calculated: 
1. Likelihood ratio of the positive test (LR+) is the ratio of sensitivity and false 
positive ratio (1–specificity): 
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2 Likelihood ratio of the negative test (LR-) the ratio of sensitivity and false negative 
ratio (1–sensitivity) and specificity: 
LR- = 1- sensitivity / specificity  
Likelihood  ratio  shows  how  the  test  result  can  alter  the  pretest  disease 
probability. LR+ shows how much the test result increases disease probability, LR- 
shows how much the test result decreases disease probability.  
Likelihood ratios are not under the influence of the disease prevalence. 
Likelihood ratio can help measuring the posttest probability. How big the 
change from pretest to posttest probability is, depends considerably on the values of 
the likelihood ratio. It is desirable for (LR+) to have the highest values and (LR–) to 
have values close to 0. For calculating the posttest disease probability, posttest odds 
are first to be calculated: 
1. For positive test result: 
Posttest odds = pretest odds × LR+ 
2. For negative test result: 
Posttest odds = pretest odds × LR– 
Posttest probability is obtained by the formula: 
Posttest probability= posttest odds/1+ posttest odds 
According to the literature data, the diagnostic accuracy of the combined test, in 
relation to the result of the early amniocentesis (referral standard) is: sensitivity 0.88, 
specificity 0.90. In our sample sensitivity is 0.94 and specificity 0.99. 
Likelihood ratios: 
LR+ =0.94/1-0.99=94.00 
LR− =1-0.94/0.99=0.06 
Pretest probability that the pregnant woman carries the fetus with the chromosomal 
abnormality is 1:250=0.004 
Pretest odds =0.004/0.996=0.004  
If the test is positive: 
Posttest odds = pretest odds x LR+ = 0.004 x 94 = 0.3760 
Posttest probability=posttest odds/1+ posttest odds=0.3760/1+0.3760=0.2732 
If the test is negative: 
Posttest odds = pretest odds × LR– = 0.004 × 0.06 = 0.00024 
Posttest probability=posttest odds/ 1+posttest odds= 0.00024/1+0.00024=0.00024. 
 
Table 5. Review of the influence of the combined test on the pretest odds and probability of the 
outcome in relation to the likelihood ratio in case of positive and negative outcome 
 
 
Pretest 
odds/ 
probability 
Posttest 
odds/ 
Positive 
test 
Posttest 
odds/ 
Negative 
test 
Likelihood 
ratio/LR+ 
Likelihood 
ratio /LR- 
Posttest 
probability/ 
Positive test 
Posttest 
probability/ 
Negative 
test 
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DISCUSSION 
In  our  research,  we  had  nine  (2.84%)  pregnant  women  with  numeric 
aberrations in total and seven (2,21%) pregnant women with structural aberrations in 
fetuses  which  could  be  explained  by  the  fact  that  the  sample  was  preselected, 
because  all  pregnant  women  were  sent  to  the  Genetic  Counseling  at  GOC  CC 
Kragujevac (Table 3), for some suspicious reason (positive personal and/or family 
case history, age of the pregnant woman, giving birth to child with chromosomal 
aberrations and/or fetal anomalies in previous pregnancies etc.). Similar results were 
reported  in  the  study  conducted  in  Great  Britain  in  2000,  stating  that  the  total 
incidence of Down syndrome 2, 1 on 1000 deliveries, which was 50% more than in 
the national reports, WALD et al. (2003). The importance of the nuchal translucency 
(NT) measurement in screening DS during the first trimester of the pregnancy was 
recognized back in 1990. With the limit value of 3mm nuchal translucency thickness, 
the detection rate DR is 64%, STOJILJKOVIĆ- MIKIĆ  and RODECK (2003); HADDOW et 
al. (1998). Screening sensitivity of chromosomopathies in comparison to NT was 
75%  with the value  of false positive ratio  of 2.1%,  WALD (1996);  PIDOUX et al. 
(2007).  In  our  sample  11  pregnant  women  in  total  from  the  group  of  16  had 
measured  value  of  NT  above  the  median  for  the  given  CRL  in  the  group  of 
pathological karyotypes that was 68, 75%. By the analysis of the total sample we 
find that with 26 pregnant women we measure NT of 2.55mm above median for the 
given CRL and by invasive diagnostics we confirm 16 cases of chromosomal fetal 
aberrations  or  61.54%  (Table  2).  Methodology  of  the  combined  test  (Table  1) 
indicates that the ultrasound screening is done first and after that to set the level of 
Free ß HCG-а and PAPP-A, whereas risks are calculated as the combination of these 
two information, WALD et al. (1996). For a certain gestation, level of Free β-HCG 
and PAPP-A represents the factor of probability which is multiplied with the initial 
risk in order to calculate the new one,  SNIJDERS et al. (1996). Difference in the 
concentration of free β-HCG between normal pregnancies and those with trisomy 21 
is increasing, and difference in the level of PAPP-A is decreasing with the age of the 
pregnancy. There is no significant connection between thicknesses of the fetal NT, 
level of free β-HCG or PAPP-A in maternal serum in pregnancies with trisomy 21 in 
relation to the normal pregnancies, so ultrasound and biochemical markers can be 
combined in order to get more efficient screening. Numerous studies have confirmed 
the connection between the low level of PAPP-A and trisomy 21 during the first 
trimester, SPENCER (2001); WALD et al. (2003a); MALONE et al. (2003). In normal 
pregnancies level of PAPP-A in maternal blood is increasing with gestation, and in 
pregnancies  with  trisomy  21  is  decreasing  (MoM<0.5).  By  setting  the  value  of 
PAPP-A, it is possible to detect 52% of DS cases with 5% false positive results, 
SPENCER (2001). In pregnancies with trisomy 21, the level of free beta-subunit of 
choriogonadotropin (Free β-HCG) is increased between 8 and 14 week of gestation, 
LONČAR et al. (2010); PIDOUX et al. (2007). The level of free β HCG in maternal 
blood decreases normally with the gestation, and in pregnancies with trisomy 21 
level of free β HCG increases (MoM>2.0), CUNNINGHAM et al. (2005); WELLESLEY 
et al. (2002). On the basis of free β-HCG level, detection rate DR amounts to 42% D.LONČAR: COMBINED TEST IN PRENATAL DIAGNOSTICS                                                      293 
with 5% false positive findings, LONČAR et al. (2010). Frequency of false positive 
results, according to the available literature, is estimated at 5%, HALLAHAN et al. 
(2000); BRIGATTI, MALONE (2004); NICOLAIDES (2004); SPENCER et al. (2004). Our 
research has shown that the rate of the false positive findings is 1%, and that free β 
HCG  is  more  sensitive  predictor  than  PAPP-A.  Other  authors  have  reported  the 
identical  conclusion,  NICOLAIDES  (2004).  Predictive  value  of  the  individual 
biochemical markers is represented at the charts 1 and 2 by setting the area below 
ROC  curve.  In  final  result  review  of  the  combined  test  predictive  value  of  our 
sample of pregnant women, we find the following facts: sensitivity of the test is 
94%, specificity is 99%. Positive predictive value of the test is 0.83, and negative 
predictive value of the test is 0.99 (99%). Positive likelihood ratio (LR +) is 94.00 
and negative likelihood ratio (LR -) is 0.06 (Tables No. 4 and 5). We have confirmed 
already published positive qualifications of this screening method, LONČAR  et al. 
(2010); KRANTZ (2000); CROSSLEY et al. (2002) and pointed out to its justification in 
every day clinical practice, SPENCER et al. (2000) regarding that posttest odds rate in 
case of  positive screening increases several times over (almost 90 times). In the 
available  literature  we  don’t  find  the  reports  that  have  the  calculation  of  the 
credibility of the combined test and prediction  of posttest odds of this screening 
method.  It  is  very  important  to  mention  to  the  patients  that  it  is  the  process  of 
screening and not the final diagnosis, CROSSLEY et al. (2002). It can be given only on 
the basis of invasive intervention and defining of the fetal karyotype.  
 
CONCLUSION 
A. By examining the sensitivity and specificity of the combined screening test in the 
period of  11.-13+6 weeks of gestation, we find that sensitivity of the test is 0.94 
(94%), and its specificity 0.99 (99%).  
B.  Pretest  probability  that  the  pregnant  woman  carries  the  fetus  with  the 
chromosomal abnormality is 1:250 or 0.004. Posttest odds after the combined test to 
discover this abnormality is 0.3760, and probability of the same case is 0.2732 if it 
happens that the test result is positive. 
C. Posttest  odds  after the  combined  test  and the  probability  of the  same  case  is 
identical if it happens that the test result is negative and amounts to 0,0002. 
 
List of Abbreviations 
CRL - embryonic crown-rump length 
NT - fetal nuchal translucency 
Free βHCG - free beta-subunit of choriogonadotropin 
PAPP-A - pregnancy-associated plasma protein A 
MoM - Multiple of the Median 
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I z v o d 
Kongenitаlne аnomаlije su uzrok perinаtаlne smrti u 20-25% slučаjevа, dok se 3% 
dece  rodi  sа  većom  ili  mаnjom  mаlformаcijom.  Cilj  rada  je  bio  da  se  ispita 
prediktivna vrednost i odredi odnos verodostojnosti rezultаtа kombinovаnog testа. 
Od  317  ispitanih  trudnica  imаli  smo  šesnaest  (5.05%)  trudnica  sa  patološkim 
rezultatom kariotipa nakon amniocenteze i to: devet (2.84%) trudnicа sа numeričkim 
аberаcijаmа fetusа i sedam (2.21%) trudnica sa strukturnim aberacijama kod fetusa. 
Pri  određivanju  ultrasonografskih  parametara  kombinovanog  testa  koristili  smo 
standarde Fondacije za fetalnu medicinu. Kvаntitаtivnа određivаnjа Free β HCG i 
PAPP-A  vršili  smo  iz  venske  krvi  pаcijentkinjа  primenom  komercijаlnih  testovа 
firme  DPS-USA.  Testovi  se  zаsnivаju  nа  аnаlitičkom  principu 
imunohemiluminiscencije  i  reаlizovаni  su  upotrebom  аutomаtskog  аnаlizаtorа 
IMMULITE 2000. Proizvođаč аnаlizаtorа je tаkođe firmа DPC-USA. Senzitivnost 
testа je 94%, specifičnost 99%. Pozitivni fаktor verovаtnoće [likelihood ratio test 
(LR +)] iznosi 94.00, а negаtivni fаktor verovаtnoće [likelihood ratio test (LR-)] 
0.06. Pretest verovаtnoćа dа trudnicа nosi plod sа hromozomskom аbnormаlnošću je 
1:250 ili 0.004. Posttest šаnsа nаkon kombinovаnog testа dа se ovа аbnormаlnost 
otkrije  je 0.3760, а verovаtnoćа istog dešаvаnjа je 0.2732 pod uslovom dа je rezultаt 
testа  pozitivаn.  Rezultаt  nаšeg  istrаživаnjа  potvrđuje  oprаvdаnost  upotrebe 
kombinovanog  testa  u  svаkodnevnoj  kliničkoj  prаksi  obzirom  dа  se  odds  rate 
posttestа (posttest šansa) u slučаju pozitivnog skriningа povećаvа višestruko (skoro 
90  putа),  a  verovatnoća  otkrivanja  hromozomske  abnormalnosti  oko  70  puta. 
Kombinovаni skrining test аko se metodološki isprаvno upotrebljаvа  imа visoku 
prediktivnu vrednost u otkrivаnju urođenih fetаlnih аnomаlijа.  
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